Enhanced CEA-specific Immune Responses by Tat-LLO Fusion Protein
Immune Network
;
: 172-178, 2005.
Article
in Korean
| WPRIM
| ID: wpr-57216
ABSTRACT
BACKGROUND:
Carcinoembryonic antigen (CEA) is well-known soluble tumor marker frequently detectable in peripheral blood of carcinoma patients and considered as good target for antigen-specific immunotherapy. However, it is known that the induction of immune response to CEA is very difficult because CEA is a self-antigen expressed in fetal cells and weakly expressed in normal colorectal epithelial cells. To enhance anti-tumor immunity specific for CEA, recombinant CEA protein was modified using listeriolysin O (LLO) for endosomal lysis and transactivator of transcription (Tat) domain for transducing extracellular proteins into cytoplasm.METHODS:
After immunization using dendritic cells pulsed with Tat-CEA, both Tat-CEA and LLO, and both Tat-CEA and Tat-LLO, antibody titer to CEA and LLO, cytotoxic T lymphocyte activity and the frequency of IFN-gamma producing T lymphocytes were measured.RESULTS:
Immunization using DC pulsed with both Tat-CEA and Tat-LLO protein showed the increasement of production of CEA-specific antibody in serum, cytotoxic T lymphocyte activity, the frequency of IFN-gamma secreting T cells, compared with DC pulsed with both Tat-CEA and LLO. Furthermore the ratio of CD8+ T cell to CD4+ T cell among CEA-specific T cells was increased in group pulsed with both Tat-CEA and Tat-LLO.CONCLUSION:
These results suggested that DC vaccine using Tat-LLO could be used for the development of effective immunotherapy for the treatment of tumor.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Dendritic Cells
/
Lymphocytes
/
T-Lymphocytes
/
Carcinoembryonic Antigen
/
Trans-Activators
/
Immunization
/
Cytoplasm
/
Epithelial Cells
/
Immunotherapy
Limits:
Humans
Language:
Korean
Journal:
Immune Network
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS